Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
- PMID: 26892034
- PMCID: PMC4839046
- DOI: 10.1007/s00296-016-3436-0
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies
Abstract
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed and nonlicensed) based on their proven efficacy in treating different clinical manifestations associated with psoriasis and PsA. This review presents the level of evidence of efficacy of different biologic treatments and small molecule inhibitors for certain clinical features of treatment of PsA and psoriasis, which was graded in categories I-IV. The literature searches were performed on the following classes of biologic agents and small molecules: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), anti-IL12/IL23 (ustekinumab), anti-IL17 (secukinumab, brodalumab, ixekizumab), anti-IL6 (tocilizumab), T cell modulators (alefacept, efalizumab, abatacept, itolizumab), B cell depletion therapy (rituximab), phosphodiesterase 4 inhibitor (apremilast) and Janus kinase inhibitor (tofacitinib). A comprehensive table including 17 different biologic agents and small molecule inhibitors previously tested in psoriasis and PsA was generated, including the level of evidence of their efficacy for each of the clinical features included in our review (axial and peripheral arthritis, enthesitis, dactylitis, and nail and skin disease). We also proposed a limited set of recommendations for a sequential biologic treatment algorithm for patients with PsA who failed the first anti-TNF therapy, based on the available literature data. There is good evidence that many of the biologic treatments initially tested in psoriasis are also effective in PsA. Further research into both prognostic biomarkers and patient stratification is required to allow clinicians the possibility to make better use of the various biologic treatment options available. This review showed that there are many potentially new treatments that are not included in the current guidelines that can be used for selected categories of patients based on their disease phenotype, clinician experience and access to new biologic therapies.
Keywords: Biologic treatments; Level of evidence of biologic agents efficacy; Psoriasis; Psoriatic arthritis; Small molecule inhibitors.
Similar articles
-
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.BioDrugs. 2013 Aug;27(4):359-73. doi: 10.1007/s40259-013-0025-6. BioDrugs. 2013. PMID: 23580094 Review.
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review.
-
New targets in psoriatic arthritis.Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii30-ii37. doi: 10.1093/rheumatology/kew343. Rheumatology (Oxford). 2016. PMID: 27856658 Review.
-
Emerging drugs for psoriatic arthritis.Expert Opin Emerg Drugs. 2016;21(1):69-79. doi: 10.1517/14728214.2016.1146679. Epub 2016 Feb 15. Expert Opin Emerg Drugs. 2016. PMID: 26807876 Review.
-
Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774. Epub 2015 Sep 30. J Med Econ. 2016. PMID: 26337538
Cited by
-
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.Curr Ther Res Clin Exp. 2020 Aug 12;93:100601. doi: 10.1016/j.curtheres.2020.100601. eCollection 2020. Curr Ther Res Clin Exp. 2020. PMID: 32983284 Free PMC article.
-
Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.Front Pharmacol. 2019 Sep 11;10:965. doi: 10.3389/fphar.2019.00965. eCollection 2019. Front Pharmacol. 2019. PMID: 31572173 Free PMC article.
-
Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists.Am J Clin Dermatol. 2018 Dec;19(6):839-852. doi: 10.1007/s40257-018-0377-2. Am J Clin Dermatol. 2018. PMID: 30117018 Free PMC article. Review.
-
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs.Paediatr Drugs. 2024 May;26(3):217-228. doi: 10.1007/s40272-023-00618-2. Epub 2024 Feb 4. Paediatr Drugs. 2024. PMID: 38310623 Review.
-
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules.Antibodies (Basel). 2024 Sep 14;13(3):76. doi: 10.3390/antib13030076. Antibodies (Basel). 2024. PMID: 39311381 Free PMC article. Review.
References
-
- Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol. 2006;33(7):1228–1230. - PubMed
-
- Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–326. doi: 10.1136/ard.2011.150995. - DOI - PubMed
-
- Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289. doi: 10.1002/art.21306. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous